Assembly Biosciences (FRA:V7B) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:V7B Assembly Biosciences Inc FRA:V7B
37 GF Score
Price €21.85
GF Value €17.56
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:V7B vs CTNM, PRTA, RGNX: Short Interest Comparison

For the Biotechnology subindustry, Assembly Biosciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assembly Biosciences Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Short Interest falls into.


FRA:V7B
37GF Score
Assembly Biosciences Inc FRA:V7B
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Assembly Biosciences (FRA:V7B) Overvalued in 2026?

Based on GuruFocus' analysis, Assembly Biosciences stock appears to be overvalued. The current stock price of €21.85 is trading 24.4% above its estimated GF Value™ of €17.56. GuruFocus considers Assembly Biosciences to be Modestly Overvalued.

Key valuation signals for FRA:V7B:

  • Short Interest:
  • GF Value™: €17.56 vs. price of €21.85 (24.4% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the FRA:V7B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Assembly Biosciences Business Description

Other Exchanges ASMB:USAV7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
37GF Score

Get the complete analysis for FRA:V7B

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.85
Price
€17.56
GF Value